MD+DI Senior Editor Amanda Pedersen highlights Bryan Hanson’s leadership and his pivotal role in driving Solventum’s progress ...

Ensera Design’s Maartje Pel discusses how medtech is embracing women-specific innovation to address historical gaps.

Discover Vivani Medical's GLP-1 implant offering steady, reversible drug delivery to enhance adherence and reduce unnecessary ...

Vicarious Surgical is facing delisting from the New York Stock Exchange again. This is another setback the surgical robotics firm has faced in recent months. The NYSE sent the com ...

Four major wearable tech companies are advancing blood pressure monitoring capabilities despite FDA warnings about medical ...

Staar Surgical reported a $80.4M full-year loss and 23.7% revenue decline, with analysts maintaining hold ratings as the ...

Jack Heslin of Creatz3D explores how AI and 3D printing could create personalized invasive devices while highlighting ...

Mark McCarty has arguably the deepest reservoir of experience in med tech regulatory matters in all of the trade press. His experience includes managing editorship of publications such as Warning ...

Medtronic’s diabetes spinoff, MiniMed Group, has raised $560 million in an initial public offering. The offering is priced below its initial marketed range. Originally, Medtronic offered shares for ...

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

The approval comes on the heels of competition eating into Boston Scientific’s shares in the pulsed field ablation market.

Explore how FDA's risk-averse approach to clinical decision support software regulation reveals challenges in balancing innovation and patient care.